Stay updated on T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial

Sign up to get notified when there's something new on the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision: v3.3.2 is now shown, replacing Revision: v3.2.0; this is a minor website update and does not affect trial data. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T17:46:08.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A government funding/operating-status notice banner was removed from the page. This banner did not affect the clinical trial record content or historical record details.
    Difference
    0.8%
    Check dated 2025-11-17T17:30:29.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The record history shows a change to Study Status (2021-01-19) and a subsequent change to Recruitment Status (2022-11-07) for the TRAEMOS study.
    Difference
    0.1%
    Check dated 2025-11-03T11:39:36.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Added a government-funding/status notice and upgraded version to v3.2.0; removed the old v3.1.0 tag.
    Difference
    13%
    Check dated 2025-10-05T17:20:22.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0.
    Difference
    0.3%
    Check dated 2025-09-28T10:07:26.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.0.2 and the Back to Top control was removed; overall, this is a minor UI/metadata update with no impact on core content.
    Difference
    0.8%
    Check dated 2025-09-14T00:21:18.000Z thumbnail image

Stay in the know with updates to T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the T-DM1 Osimertinib Combo for HER2 in NSCLC Clinical Trial page.